NCT03277924 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03277924
Title	Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc)
Acronym	ImmunoSarc
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Grupo Espanol de Investigacion en Sarcomas
Indications	extraskeletal myxoid chondrosarcoma malignant fibrous histiocytoma osteosarcoma malignant epithelioid hemangioendothelioma leiomyosarcoma alveolar soft part sarcoma solitary fibrous tumor/hemangiopericytoma chondrosarcoma angiosarcoma clear cell sarcoma
Therapies	Nivolumab + Sunitinib
Age Groups:	adult \| child \| senior
Covered Countries	ITA \| GBR \| ESP

No variant requirements are available.